The misfolding of the antioxidant enzyme superoxide dismutase1 (SOD1) in motor neurons may contribute to ALS. A human-derived monoclonal antibody directed to misfolded SOD1, Neurimmune’s NI-204 aims to reduce the accumulation of misfolded SOD1 within motor neurons in people with ALS and thereby slow the progression of the disease.
Targeting misfolded SOD1, according to a growing number of studies, could be important in both the treatment of sporadic and familial forms of ALS. We look forward to further evaluating these antibodies as a potential treatment for the disease.
Emerging strategies targeting misfolded SOD1 aim to slow or stop the spread of ALS - even in sporadic disease.
A new map may help scientists design potential medicines that stop ALS in its tracks.
PALS that produce antibodies targeting misfolded SOD1 appear to live significantly longer according to a small study.
Elevated levels of antibodies directed against misfolded SOD1 may be protective in people with sALS.
Treatment with Neurimmune mSOD1 antibodies appeared to significantly reduce motor decline and extend survival of a SOD1 mouse model according to preliminary results presented at ALS/MND 2013.
Topics in the Pipeline
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!
Stay up to date with ALS TDI by subscribing to our newsletter today!